Quantum Genomics S.A. (QNNTF)
Quantum Genomics S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Paris, FR. The stock last traded at $0.10, up 0.00% on the session, giving a market capitalisation of $7.0M. On trailing twelve-month figures it carries a trailing P/E of -0.55, a net margin of -88926030.0%. Its beta of 0.16 implies it has historically moved less than the broad market.
Quantum Genomics S.A., a biopharmaceutical enterprise headquartered in Paris, France, was established in 2005. The company specializes in advancing therapeutic solutions for cardiovascular ailments. Its drug development efforts are anchored in the brain aminopeptidase A inhibition (BAPAI) platform, primarily targeting hypertension (high blood pressure) and heart failure. Among its pipeline, firibastat is a notable candidate, currently undergoing a crucial Phase III study as a standalone treatment for high blood pressure, and is also progressing through clinical trials for heart failure. Furthermore, Quantum Genomics is developing QGC011 for combination therapy in hypertension, alongside QGC006 and QGC606, which are designed to address both hypertension and heart failure.
Quantum Genomics S.A. is most often compared with the following Healthcare names: